Spire Healthcare Group plc (SPI.L), a provider of private healthcare in the UK, Thursday reported profit before tax of 22.7 million pounds for the first half, 11.8 percent higher than 20.3 million pounds in the comparable period last year, mainly driven by strong demand for private and NHS healthcare.Excluding one-time items, adjusted profit before tax increased 20.2 percent year-on-year to 26.8 million pounds from 22.3 million pounds.Operating profit grew 8.8 percent to 71.6 million pounds from 65.8 million pounds a year ago, while adjusted operating profit rose 11.7 percent to 75.7 million pounds from 67.8 million pounds.Adjusted EBITDA or adjusted earnings before interest, taxes, depreciation, and amortization rose 10.8 percent to 130.6 million pounds.Net profit was 14.1 million pounds or 3.2p per share, up from 12.7 million pounds or 3.0p per share in the prior year..

英国私人医疗保健提供商Spire Healthcare Group plc（SPI.L）周四公布，上半年税前利润为2270万英镑，比去年同期的2030万英镑高11.8%，主要是由于对私人和NHS医疗保健的强劲需求。不包括一次性项目，调整后的税前利润同比增长20.2%，从2230万英镑增至2680万英镑。。调整后息税折旧摊销前利润或调整后息税折旧摊销前利润增长10.8%，至1.306亿英镑。净利润为1410万英镑，每股3.2便士，高于上年的1270万英镑，每股3.0便士。。

Adjusted profit grew to 19.6 million pounds or 4.6p per share from 14.2 million pounds or 3.4p per share last year.Revenue for the period increased 12.7 percent to 762.5 million pounds from 676.5 million pounds in the previous year.Looking ahead, the company continues to expect full-year adjusted EBITDA of 255 million pounds - 275 million pounds.

调整后的利润从去年的1420万英镑或每股3.4便士增至1960万英镑或每股4.6便士。这一时期的收入增长了12.7%，从去年的6.765亿英镑增至7.625亿英镑。展望未来，该公司预计全年调整后息税折旧摊销前利润将达到2.55亿英镑-2.75亿英镑。

For comments and feedback contact: editorial@rttnews.comBusiness News.

如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In August 2024

2024年8月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In June 2024

2024年6月美国食品和药物管理局决定生物技术股

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股